Oral Cancer Prevention International and CDx Laboratories have combined forces as CDx Diagnostics.
The two companies are focused on developing diagnostic systems designed to help prevent cancer by detecting precancerous cells.
CDx Laboratories was founded in 1997 to develop tools to detect dysplasia in tissues for which no practical and accurate tests were available, according to the companies. Oral Cancer Prevention International was founded in 2007 and licensed the CDx technology platform to detect precancerous cells in the mouth. Its OralCDx brush biopsy test for oral precancer and cancer is currently utilized by thousands of U.S. physicians and dentists, according to CDx.
"We are pleased to be able to consolidate our oral, esophageal, and laryngeal cancer diagnostic assets into one company that can better leverage our investment in the proprietary computer algorithms and systems that we have developed to improve the detection of precancerous cells," said Mark Rutenberg, chairman and CEO of CDx Diagnostics, in a press release. "There are tremendous synergies here because dysplasia in any part of the body has a lot of similarities. So the techniques we have used to help detect dysplasia in the esophagus help us do the same in the mouth, and vice versa."
The merger was facilitated by a new investment in CDx Diagnostics made by Waterbridge Capital, a New York City-based investment firm.